Aileron Therapeutics Inc (NASDAQ:ALRN) major shareholder Bioventures Ltd Novartis sold 190,338 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $2.06, for a total value of $392,096.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
NASDAQ:ALRN traded down $0.02 during mid-day trading on Friday, reaching $1.90. The company’s stock had a trading volume of 209,700 shares, compared to its average volume of 353,694. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.19. Aileron Therapeutics Inc has a twelve month low of $0.52 and a twelve month high of $9.50. The firm has a market cap of $28.17 million, a price-to-earnings ratio of -1.07 and a beta of 3.18.
A number of analysts have issued reports on ALRN shares. HC Wainwright started coverage on Aileron Therapeutics in a research note on Monday. They issued a “buy” rating and a $7.00 price target on the stock. ValuEngine lowered Aileron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research raised Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Tuesday, January 8th.
A number of large investors have recently modified their holdings of the business. Vanguard Group Inc boosted its stake in Aileron Therapeutics by 8.0% in the 3rd quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock worth $265,000 after buying an additional 7,109 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Aileron Therapeutics in the 3rd quarter worth about $137,000. Bridgeway Capital Management Inc. lifted its stake in shares of Aileron Therapeutics by 78.6% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock valued at $312,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Parkwood LLC acquired a new position in shares of Aileron Therapeutics in the 3rd quarter valued at about $149,000. 9.16% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Bioventures Ltd Novartis Sells 190,338 Shares of Aileron Therapeutics Inc (ALRN) Stock” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://transcriptdaily.com/2019/03/16/bioventures-ltd-novartis-sells-190338-shares-of-aileron-therapeutics-inc-alrn-stock.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Story: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.